Thursday, 12 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The real-time risk premium for crude oil is $18/bbl, corresponding to estimate of impact of six-week full halt to tanker traffic in Strait of Hormuz

    80% confidence
  • Four of six tanks at Saudi Arabia's Ras Tanura refinery were full, and Ju'aymah terminal on country's east coast is quickly running out of spare capacity

    80% confidence
  • We will set fire to any ship attempting to pass through the strait

    80% confidence
  • Upgraded Target to outperform from market perform with price target of $145

    80% confidence
  • Proposed 15% tariffs on goods imported into US may take effect this week

    80% confidence
  • Initiated coverage on nLight with recommendation of outperform and price target of $95

    80% confidence
  • It's important to drive inflation back to target

    80% confidence
  • Fed policy could be on hold for quite some time

    80% confidence
  • Excluding Magnificent Seven megacap technology stocks, Q4 earnings expected to increase by 4.6%

    80% confidence
  • Iranian operatives from Ministry of Intelligence used backchannels to contact CIA a day after US-Israeli attacks began

    80% confidence
  • Downgraded Frontline to hold from buy

    80% confidence
  • S&P earnings growth expected to climb by 8.4% in Q4, marking tenth consecutive quarter of year-over-year growth

    80% confidence
  • Upgraded Dow to overweight from sector weight with price target of $38

    80% confidence
  • US will ensure the free flow of energy through the Strait of Hormuz with insurance guarantees and even naval escorts

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com